share_log

Benchmark Reiterates Buy on Biofrontera, Maintains $7 Price Target

Benzinga ·  May 15, 2023 09:29

Benchmark analyst Bruce Jackson reiterates Biofrontera (NASDAQ:BFRI) with a Buy and maintains $7 price target.

Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more
    Write a comment